Works matching IS 11707690 AND DT 2025 AND VI 43 AND IP 4
Results: 8
Projections of Public Spending on Pharmaceuticals: A Review of Methods: Projections of Public Spending on Pharmaceuticals: I. Odnoletkova et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 4, p. 375, doi. 10.1007/s40273-024-01465-w
- By:
- Publication type:
- Article
Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness: Cost-Effectiveness of Bladder Cancer Screening: Microsimulation: O. Mandrik et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 4, p. 441, doi. 10.1007/s40273-024-01463-y
- By:
- Publication type:
- Article
Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma: CEA of Exclusionary EGFR Testing: H.-T. Ou et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 4, p. 429, doi. 10.1007/s40273-024-01462-z
- By:
- Publication type:
- Article
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment: Value of Innovative Multiple Myeloma Treatments: S. Syeed et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 4, p. 403, doi. 10.1007/s40273-024-01459-8
- By:
- Publication type:
- Article
Examination of Methods to Estimate Productivity Losses in an Economic Evaluation: Using Foodborne Illness as a Case Study: Estimating Productivity Losses in an Economic Evaluation: Case Study Using Foodborne Illness: K. Manipis et al.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 4, p. 453, doi. 10.1007/s40273-024-01458-9
- By:
- Publication type:
- Article
How Does Bereavement Affect the Health-Related Quality of Life of Household Members Who Do and Do Not Provide Unpaid Care? Difference-in-Differences Analyses Using the UK Household Longitudinal Survey: How Does Bereavement Affect the Health-Related Quality of Life: B. Pennington et al
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 4, p. 389, doi. 10.1007/s40273-024-01452-1
- By:
- Publication type:
- Article
A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence: Pricing and Reimbursement of New Pharmaceuticals in an Evolving Landscape: B. Woods et al
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 4, p. 363, doi. 10.1007/s40273-024-01450-3
- By:
- Publication type:
- Article
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs: Indication-Specific Pricing and Weighted-Average Pricing: D. T. Michaeli, T. Michaeli.
- Published in:
- PharmacoEconomics, 2025, v. 43, n. 4, p. 415, doi. 10.1007/s40273-024-01448-x
- By:
- Publication type:
- Article